vs

Side-by-side financial comparison of Backblaze, Inc. (BLZE) and RECURSION PHARMACEUTICALS, INC. (RXRX). Click either name above to swap in a different company.

Backblaze, Inc. is the larger business by last-quarter revenue ($37.8M vs $35.5M, roughly 1.1× RECURSION PHARMACEUTICALS, INC.). Backblaze, Inc. runs the higher net margin — -14.3% vs -304.2%, a 289.9% gap on every dollar of revenue. On growth, RECURSION PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (681.7% vs 11.8%). Backblaze, Inc. produced more free cash flow last quarter ($9.0M vs $-47.3M). Over the past eight quarters, RECURSION PHARMACEUTICALS, INC.'s revenue compounded faster (60.5% CAGR vs 12.3%).

Backblaze, Inc. is an American cloud storage and data backup company based in San Mateo, California. It was founded in 2007 by Gleb Budman and others. Its services are intended for both business and personal markets.

Recursion Pharmaceuticals is a clinical-stage biotechnology company that combines artificial intelligence and large-scale high-throughput biological experimentation to discover and develop innovative therapies for rare diseases, oncology, inflammatory disorders, and other areas of unmet medical need. It primarily operates in North America and partners with global biopharmaceutical firms to advance its robust therapeutic pipeline.

BLZE vs RXRX — Head-to-Head

Bigger by revenue
BLZE
BLZE
1.1× larger
BLZE
$37.8M
$35.5M
RXRX
Growing faster (revenue YoY)
RXRX
RXRX
+670.0% gap
RXRX
681.7%
11.8%
BLZE
Higher net margin
BLZE
BLZE
289.9% more per $
BLZE
-14.3%
-304.2%
RXRX
More free cash flow
BLZE
BLZE
$56.4M more FCF
BLZE
$9.0M
$-47.3M
RXRX
Faster 2-yr revenue CAGR
RXRX
RXRX
Annualised
RXRX
60.5%
12.3%
BLZE

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
BLZE
BLZE
RXRX
RXRX
Revenue
$37.8M
$35.5M
Net Profit
$-5.4M
$-108.1M
Gross Margin
62.0%
59.8%
Operating Margin
-12.4%
-304.8%
Net Margin
-14.3%
-304.2%
Revenue YoY
11.8%
681.7%
Net Profit YoY
62.3%
39.6%
EPS (diluted)
$-0.09
$-0.17

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BLZE
BLZE
RXRX
RXRX
Q4 25
$37.8M
$35.5M
Q3 25
$37.2M
$5.2M
Q2 25
$36.3M
$19.2M
Q1 25
$34.6M
$14.7M
Q4 24
$33.8M
$4.5M
Q3 24
$32.6M
$26.1M
Q2 24
$31.3M
$14.4M
Q1 24
$30.0M
$13.8M
Net Profit
BLZE
BLZE
RXRX
RXRX
Q4 25
$-5.4M
$-108.1M
Q3 25
$-3.8M
$-162.3M
Q2 25
$-7.1M
$-171.9M
Q1 25
$-9.3M
$-202.5M
Q4 24
$-14.4M
$-178.9M
Q3 24
$-12.8M
$-95.8M
Q2 24
$-10.3M
$-97.5M
Q1 24
$-11.1M
$-91.4M
Gross Margin
BLZE
BLZE
RXRX
RXRX
Q4 25
62.0%
59.8%
Q3 25
62.1%
-183.8%
Q2 25
63.5%
-4.9%
Q1 25
55.6%
-48.0%
Q4 24
54.8%
-181.4%
Q3 24
54.6%
53.7%
Q2 24
55.1%
36.2%
Q1 24
52.8%
19.1%
Operating Margin
BLZE
BLZE
RXRX
RXRX
Q4 25
-12.4%
-304.8%
Q3 25
-8.9%
-3327.6%
Q2 25
-18.5%
-916.8%
Q1 25
-25.8%
-1297.9%
Q4 24
-40.8%
-4042.4%
Q3 24
-37.4%
-377.1%
Q2 24
-31.4%
-697.4%
Q1 24
-35.1%
-698.4%
Net Margin
BLZE
BLZE
RXRX
RXRX
Q4 25
-14.3%
-304.2%
Q3 25
-10.2%
-3135.3%
Q2 25
-19.6%
-894.2%
Q1 25
-26.9%
-1373.3%
Q4 24
-42.6%
-3935.5%
Q3 24
-39.1%
-367.5%
Q2 24
-33.1%
-676.6%
Q1 24
-36.9%
-662.4%
EPS (diluted)
BLZE
BLZE
RXRX
RXRX
Q4 25
$-0.09
$-0.17
Q3 25
$-0.07
$-0.36
Q2 25
$-0.13
$-0.41
Q1 25
$-0.17
$-0.50
Q4 24
$-0.30
$-0.56
Q3 24
$-0.29
$-0.34
Q2 24
$-0.25
$-0.40
Q1 24
$-0.27
$-0.39

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BLZE
BLZE
RXRX
RXRX
Cash + ST InvestmentsLiquidity on hand
$51.4M
$743.3M
Total DebtLower is stronger
$9.6M
Stockholders' EquityBook value
$83.2M
$1.1B
Total Assets
$191.8M
$1.5B
Debt / EquityLower = less leverage
0.01×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BLZE
BLZE
RXRX
RXRX
Q4 25
$51.4M
$743.3M
Q3 25
$50.3M
$659.8M
Q2 25
$50.5M
$525.1M
Q1 25
$53.2M
$500.5M
Q4 24
$54.9M
$594.4M
Q3 24
$20.9M
$427.6M
Q2 24
$23.6M
$474.3M
Q1 24
$28.2M
$296.3M
Total Debt
BLZE
BLZE
RXRX
RXRX
Q4 25
$9.6M
Q3 25
$11.9M
Q2 25
$14.2M
Q1 25
$16.4M
Q4 24
$19.0M
Q3 24
$20.5M
Q2 24
$22.9M
Q1 24
Stockholders' Equity
BLZE
BLZE
RXRX
RXRX
Q4 25
$83.2M
$1.1B
Q3 25
$82.8M
$1.0B
Q2 25
$79.6M
$919.1M
Q1 25
$77.8M
$933.9M
Q4 24
$77.6M
$1.0B
Q3 24
$42.8M
$524.6M
Q2 24
$45.1M
$584.4M
Q1 24
$47.5M
$401.2M
Total Assets
BLZE
BLZE
RXRX
RXRX
Q4 25
$191.8M
$1.5B
Q3 25
$191.5M
$1.4B
Q2 25
$186.0M
$1.3B
Q1 25
$170.2M
$1.3B
Q4 24
$168.6M
$1.4B
Q3 24
$136.2M
$726.5M
Q2 24
$127.8M
$775.9M
Q1 24
$131.9M
$557.8M
Debt / Equity
BLZE
BLZE
RXRX
RXRX
Q4 25
0.01×
Q3 25
0.01×
Q2 25
0.02×
Q1 25
0.02×
Q4 24
0.02×
Q3 24
0.04×
Q2 24
0.04×
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BLZE
BLZE
RXRX
RXRX
Operating Cash FlowLast quarter
$9.3M
$-46.1M
Free Cash FlowOCF − Capex
$9.0M
$-47.3M
FCF MarginFCF / Revenue
24.0%
-133.1%
Capex IntensityCapex / Revenue
0.7%
3.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$18.9M
$-378.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BLZE
BLZE
RXRX
RXRX
Q4 25
$9.3M
$-46.1M
Q3 25
$5.7M
$-117.4M
Q2 25
$3.5M
$-76.4M
Q1 25
$4.9M
$-132.0M
Q4 24
$2.2M
$-115.4M
Q3 24
$4.6M
$-59.2M
Q2 24
$2.2M
$-82.2M
Q1 24
$3.4M
$-102.3M
Free Cash Flow
BLZE
BLZE
RXRX
RXRX
Q4 25
$9.0M
$-47.3M
Q3 25
$2.6M
$-117.6M
Q2 25
$2.8M
$-79.6M
Q1 25
$4.4M
$-133.8M
Q4 24
$1.4M
$-116.7M
Q3 24
$4.4M
$-63.8M
Q2 24
$2.0M
$-83.4M
Q1 24
$3.0M
$-109.0M
FCF Margin
BLZE
BLZE
RXRX
RXRX
Q4 25
24.0%
-133.1%
Q3 25
7.0%
-2272.5%
Q2 25
7.6%
-413.9%
Q1 25
12.8%
-907.4%
Q4 24
4.2%
-2567.7%
Q3 24
13.6%
-244.6%
Q2 24
6.3%
-578.5%
Q1 24
10.0%
-789.9%
Capex Intensity
BLZE
BLZE
RXRX
RXRX
Q4 25
0.7%
3.5%
Q3 25
8.5%
4.7%
Q2 25
2.2%
16.4%
Q1 25
1.5%
12.4%
Q4 24
2.4%
28.6%
Q3 24
0.6%
17.5%
Q2 24
0.9%
8.2%
Q1 24
1.4%
48.2%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons